SPYRE THERAPEUTICS, INC.: cashflow_investing

Value{"amount": -73121000, "concept": "us-gaap:NetCashProvidedByUsedInInvestingActivities", "currency": "USD"}
Period2023-01-01 – 2023-09-30
Statuscurrent
EntitySPYRE THERAPEUTICS, INC.
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference: 0001636282-23-000018 · Open the official SEC filing →
Retrieved: 2026-08-19T16:49:38.245373+02:00
Raw response sha256: f7bde1a401b286c74a2fd824ee1df541…
Also addressable by official identifiers: https://factanker.com/fact/sec/cik-0001636282/cashflow-investing/2023-09-30 (CIK, metric, reporting date)
Cite as: FACTANKER, https://factanker.com/fact/789eaf2d-2dad-498c-9bef-c522a05d1a2c

History

From the Record
32 US software companies haven’t lost money in a decade. One of them is steadier than all the rest.
Read the findingSearch 53 million companies